CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,792,153 | -12.5% | 83,546 | +8.2% | 0.01% | 0.0% |
| Q2 2023 | $4,334,008 | -7.5% | 77,200 | -25.4% | 0.01% | -10.0% |
| Q1 2023 | $4,683,205 | +148.3% | 103,542 | +123.2% | 0.01% | +233.3% |
| Q4 2022 | $1,886,160 | -72.1% | 46,400 | -55.1% | 0.00% | -72.7% |
| Q3 2022 | $6,754,000 | +2.1% | 103,323 | -5.1% | 0.01% | +83.3% |
| Q2 2022 | $6,618,000 | +84.2% | 108,900 | +90.2% | 0.01% | +200.0% |
| Q1 2022 | $3,593,000 | -85.9% | 57,245 | -83.0% | 0.00% | -91.7% |
| Q4 2021 | $25,475,000 | -24.9% | 336,137 | +10.9% | 0.02% | -7.7% |
| Q3 2021 | $33,911,000 | -2.0% | 302,967 | +41.8% | 0.03% | -16.1% |
| Q2 2021 | $34,586,000 | +174.1% | 213,640 | +106.3% | 0.03% | +181.8% |
| Q1 2021 | $12,620,000 | – | 103,571 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |